Physician

Erin Flattery, M.D.

According to 2025 Medicare claims, Erin Flattery, M.D. (NPI: 1972036903) practices advanced heart failure and transplant cardiology in the New York-Jersey City-White Plains, NY-NJ market, with the plurality of this provider's patient population coming from Kings, NY. This provider's primary affiliated billing organization is NEW YORK UNIVERSITY (NPI: 1285826438; TIN: 472665045) and primary practice location at 10016-6402.

Flattery's data goes back to 2015 and runs through 2024. Part D data shows 216 prescription claims across 40 beneficiaries totaling $78,760 in drug costs, led by Jardiance (Empagliflozin). Open Payments data shows 7 records totaling $321. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider has fewer than 5 years of reported Medicare Part B carrier billing data, so a reliable trend cannot be assigned. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $3,212 and ending at $78,760. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

No connected Part B records

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	20	85	$3,212
2018	58	514	$57,376
2019	111	1,145	$84,247
2020	67	500	$39,916
2021	33	202	$53,316
2022	40	246	$66,265
2023	50	274	$87,124
2024	40	216	$78,760

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

No connected Part B code-level records for 2024.

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jardiance	Empagliflozin	33	1,830	$34,523
Entresto	Sacubitril/Valsartan	19	930	$20,413
Metoprolol Succinate	Metoprolol Succinate	14	1,260	$681
Carvedilol	Carvedilol	12	960	$105
Furosemide	Furosemide	21	1,290	$64

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	7	$321	Abbott Laboratories
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Erin Flattery, M.D.?

Tedicare shows public-source Medicare data for Erin Flattery, M.D. (NPI 1972036903), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Erin Flattery, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Erin Flattery, M.D.?

Erin Flattery, M.D. is linked to NEW YORK UNIVERSITY (billing NPI 1285826438) in the available physician profile data.

Does Erin Flattery, M.D. have Open Payments data?

Erin Flattery, M.D. has 7 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.